Romanian
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)

amyloid/infarction

Linkul este salvat în clipboard
15 rezultate

Modulators for amyloid beta

Numai utilizatorii înregistrați pot traduce articole
Log In / Înregistrare
PRIORITY TO RELATED APPLICATIONS(S) This application claims the benefit of European Patent Application No. 08150173.6, filed Jan. 11, 2008, which is hereby incorporated by reference in its entirety. BACKGROUND OF THE INVENTION Alzheimer's disease (AD) is the most common cause of dementia in later

Modulators of amyloid beta

Numai utilizatorii înregistrați pot traduce articole
Log In / Înregistrare
BACKGROUND OF THE INVENTION Alzheimer's disease (AD) is the most common cause of dementia in later life. Pathologically, AD is characterized by the deposition of amyloid in extracellular plaques and intracellular neurofibrillary tangles in the brain. The amyloid plaques are mainly composed of

Modulators for amyloid beta

Numai utilizatorii înregistrați pot traduce articole
Log In / Înregistrare
BACKGROUND OF THE INVENTION Alzheimer's disease (AD) is the most common cause of dementia in later life. Pathologically, AD is characterized by the deposition of amyloid in extracellular plaques and intracellular neurofibrillary tangles in the brain. The amyloid plaques are mainly composed of

Bridged piperidine derivatives

Numai utilizatorii înregistrați pot traduce articole
Log In / Înregistrare
PRIORITY TO RELATED APPLICATION(S) This application claims the benefit of European Patent Application No 11156587.5, filed Mar. 2, 2011, which is hereby incorporated by reference in its entirety. BACKGROUND OF THE INVENTION Alzheimer's disease (AD) is the most common cause of dementia in later life.

Heteroaryl substituted piperidines

Numai utilizatorii înregistrați pot traduce articole
Log In / Înregistrare
PRIORITY TO RELATED APPLICATION(S) This application claims the benefit of European Patent Application No. 10153843.7, filed Feb. 17, 2010, which is hereby incorporated by reference in its entirety. BACKGROUND OF THE INVENTION Alzheimer's disease (AD) is the most common cause of dementia in later

Heterocyclic gamma secretase modulators

Numai utilizatorii înregistrați pot traduce articole
Log In / Înregistrare
PRIORITY TO RELATED APPLICATION(S) This application claims the benefit of European Patent Application No. 08168719.6, filed Nov. 10, 2008, which is hereby incorporated by reference in its entirety. BACKGROUND OF THE INVENTION Alzheimer's disease (AD) is the most common cause of dementia in later

5,6-dihydro-imidazo[1,2-a]pyrazin-8-ylamine derivatives useful as inhibitors of beta-secretase (BACE)

Numai utilizatorii înregistrați pot traduce articole
Log In / Înregistrare
FIELD OF THE INVENTION The present invention relates to novel 5,6-dihydro-imidazo[1,2-a]pyrazin-8-ylamine derivatives as inhibitors of beta-secretase, also known as beta-site amyloid cleaving enzyme, BACE, BACE1, Asp2, or memapsin2. The invention is also directed to pharmaceutical compositions

Anti-dementia drug

Numai utilizatorii înregistrați pot traduce articole
Log In / Înregistrare
SUMMARY OF THE INVENTION The present invention relates to an anti-dementia agent which comprises rolipram (4-[3-cyclopentyloxy)-4-methoxyphenyl]-2-pyrrolidinone) as an active ingredient. As the proportion of aged people grows larger in the society, countermeasures against senile dementia causes by

Bridged piperidine derivatives

Numai utilizatorii înregistrați pot traduce articole
Log In / Înregistrare
The present invention relates to compounds of formula ##STR00002## hetaryl is a five membered heteroaryl group, containing 1 to 3 heteroatoms, selected from O, S or N; R.sup.1 is hydrogen, halogen, lower alkyl, lower alkoxy, lower alkyl substituted by halogen, S-lower alkyl substituted by halogen or

Bicyclic heteroaryl derivatives

Numai utilizatorii înregistrați pot traduce articole
Log In / Înregistrare
CROSS-REFERENCE TO RELATED APPLICATIONS This application is a National Stage Entry of PCT Application No. PCT/EP2017/074927, filed on Oct. 2, 2017, which is incorporated herein by reference in its entirety, which claims benefit of priority to European Application No. 16192237.2, filed on Oct. 4,

Bridged piperidine derivatives

Numai utilizatorii înregistrați pot traduce articole
Log In / Înregistrare
The present invention relates to a compound of formula ##STR00002## wherein HetAr is a five or six membered hetaryl group, containing one, two or three heteroatoms, selected from N, O or S; R.sup.1 is hydrogen, lower alkyl, lower alkyl substituted by halogen, halogen, or lower alkoxy; R.sup.2 is

Fused pyrimidine derivatives

Numai utilizatorii înregistrați pot traduce articole
Log In / Înregistrare
SUMMARY The present invention relates to compounds of formula I, ##STR00003## wherein R.sup.1 is phenyl, lower alkyl, C.sub.3-6-cycloalkyl, --CH.sub.2--C.sub.3-6-cycloalkyl, or bridged C.sub.3-5-cycloalkyl, optionally substituted by one, two or three substituents, selected from halogen, lower alkyl
This application is the U.S. National Phase under 35 U.S.C. .sctn.371 of International Application PCT/KR2008/003975, filed on Jul. 4, 2008, which claims priority to Korean Patent Application No. 10-2008-0064291, filed on Jul. 3, 2008 and Korean Patent Application No. 10-2007-0066887, filed on Jul.

Human G protein-coupled receptor and modulators thereof for the treatment of cell death-related disorders

Numai utilizatorii înregistrați pot traduce articole
Log In / Înregistrare
FIELD OF THE INVENTION The present invention relates to methods of identifying whether a candidate compound is a modulator of a G protein-coupled receptor (GPCR). In certain embodiments, the GPCR is human. In certain embodiments, the GPCR is expressed endogenously by neuronal cells or muscle cells.

(4-arylsulfonylamino)-tetrahydropyran-4-carboxylic acid hydroxamides

Numai utilizatorii înregistrați pot traduce articole
Log In / Înregistrare
BACKGROUND OF THE INVENTION The present invention relates to (4-arylsulfonylamino)-tetrahydropyran-4-carboxylic acid hydroxamide derivatives, and to pharmaceutical compositions and methods of treatment. The compounds of the present invention are inhibitors of zinc metalloendopeptidases, especially
Alăturați-vă paginii
noastre de facebook

Cea mai completă bază de date cu plante medicinale susținută de știință

  • Funcționează în 55 de limbi
  • Cure pe bază de plante susținute de știință
  • Recunoașterea ierburilor după imagine
  • Harta GPS interactivă - etichetați ierburile în locație (în curând)
  • Citiți publicațiile științifice legate de căutarea dvs.
  • Căutați plante medicinale după efectele lor
  • Organizați-vă interesele și rămâneți la curent cu noutățile de cercetare, studiile clinice și brevetele

Tastați un simptom sau o boală și citiți despre plante care ar putea ajuta, tastați o plantă și vedeți boli și simptome împotriva cărora este folosit.
* Toate informațiile se bazează pe cercetări științifice publicate

Google Play badgeApp Store badge